PolyPeptide Group AG
SIX: PPGN.SW0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- Swiss Exchange
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- CEO
- Juan Jose Gonzalez
- Employees
- 1,362
- Headquarters
- Baar, Switzerland
- IPO year
- 2021
- Market cap
- CHF 1.3B
- Website
- https://www.polypeptide.com
Loading PPGN…
Loading profile data…Frequently asked questions about PPGN
What does PolyPeptide Group AG (PPGN.SW) do?
PolyPeptide Group AG operate as a contract development and manufacturing company worldwide. It focuses on proprietary and generic GMP-grade peptides used by pharmaceutical and biotech companies in approved pharmaceutical products, drugs in clinical development, and in generic products. It engages in manufacturing custom research grade peptides;...
Where does PPGN.SW trade?
PolyPeptide Group AG (PPGN.SW) trades on the Swiss Exchange.
What sector is PPGN.SW in?
PolyPeptide Group AG (PPGN.SW) operates in the Healthcare sector, specifically in the Drug Manufacturers - Specialty & Generic industry.
Who is the CEO of PolyPeptide Group AG?
Juan Jose Gonzalez is the chief executive officer of PolyPeptide Group AG (PPGN.SW).
Where is PolyPeptide Group AG headquartered?
PolyPeptide Group AG is headquartered in Switzerland.
Does PPGN.SW pay a dividend?
PolyPeptide Group AG (PPGN.SW) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did PPGN.SW go public?
PolyPeptide Group AG (PPGN.SW) completed its initial public offering in 2021.